<DOC>
	<DOCNO>NCT01500538</DOCNO>
	<brief_summary>Vorinostat drug ( Histone Deacetylase Inhibitor [ HDACi ] ) administer orally approve United States patient cutaneous Tcell lymphoma ( CTCL ) progressive , persistent recurrent disease follow two systemic therapy . In early period treatment vorinostat , patient may experience low platelet count . Therefore study examine combination two medication ( Vorinostat eltrombopag ) ass eltrombopag overcome low platelet treatment vorinostat . Eltrombopag drug administer orally design mimic protein thrombopoietin , cause body make platelet . Eltrombopag register Australia approve overseas treat patient chronic ITP ( Immune Thrombocytopenia Purpura ) disease patient destroy platelet rapidly thus develop low platelet count ) register yet know whether eltrombopag increase platelet count patient treat HDACi . The aim project test whether Vorinostat eltrombopag safely combine , test whether effective participant T-cell lymphoma involve skin patient relapsed/refractory follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) A total 25 people Cutaneous T cell lymphoma/ CTCL , marginal zone lymphoma , follicular lymphoma mantle cell lymphoma recruit study .</brief_summary>
	<brief_title>A Pilot Study Oral Vorinostat Plus Oral Eltrombopag Support Patients With Lymphoma ( VEIL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Age 18years old Tcell lymphoma involve skin patient relapsed/refractory follicular lymphoma ( FL ) , marginal zone lymphoma ( MZL ) , mantle cell lymphoma ( MCL ) . Disease must confirm previous histology must measurable For patient cutaneous Tcell lymphoma : At least 2 prior systemic therapy ( include 1 month therapy systemic steroid &gt; 25mg alternate day prednisolone equivalent , total skin electronbeam radiotherapy ) . For patient B cell lymphoma , prior exposure chemotherapy regimen require , unless patient deem unfit conventional chemotherapeutic regimen . Adequate haematological function : ANC ≥ 1.0x109/L Adequate renal function ( serum creatinine clearance calculate CrCl ≥30mL/min ( perform 24hr urine creatinine clearance serum creatinine &gt; 1.5xULN ) ; electrolyte level ≥ LLN ( i.e . : potassium , total calcium [ correct serum albumin ] , magnesium phosphorus ) correctable supplement ) Adequate hepatic function : AST ALT ≤ 2.5 x ULN ( ≤ 5.0 x ULN liver infiltration ; Serum bilirubin ≤ 1.5 x ULN Life expectancy ≥ 12 week Written inform consent obtain prior study specific screening procedure ECOG performance status grade 02 Ability comply adequate contraception patient childbearing potential . Females childbearing potential must negative urine pregnancy test screen agree use medically reliable method prevent conception throughout study 30 day follow date last dose . Males female partner childbearing potential must agree use medically reliable method prevent conception throughout study 30 day follow date last dose . Mentally competent able understand information give provide informed consent . Known uncontrolled medical condition may compromise participation study include limited : Poorly control congestive heart failure : ejection fraction &lt; 30 % measure past 6 month ) NYHA class IV ; Unstable angina ischaemic cardiac event require hospital admission previous 12 month . Concomitant use another HDAC inhibitor , include sodium valproate . GI disease may significantly alter absorption eltrombopag Subjects know seropositive HIV , Hepatitis B Hepatitis C. Current participation trial study medical therapeutic intervention . Known prothrombotic condition define history ≥1 unprovoked deep venous thrombosis pulmonary embolism , DVT/PE procoagulant condition screen suggest presence procoagulant condition ( prothrombin gene mutation homozygosity , factor V Leiden homozygosity , antithrombin deficiency , lupus anticoagulant syndrome ) . History ischaemic neurological event ( TIA stroke ) within precede 2 year . Active uncontrolled infection , cutaneous infection . Prior diagnosis cancer : 5 year prior current diagnosis subsequent evidence disease recurrence estimate clinical expectation recurrence great 10 % within next 2 year ; within 5 year current diagnosis exception successfully treat basal cell squamous cell skin carcinoma , carcinoma situ cervix localise cancer treat curatively local therapy Use another anticancer treatment within 21 day start vorinostat , exception steroid , interferon oral methotrexate stable dose least 4 week prior day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Marginal zone lymphoma</keyword>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>vorinostat</keyword>
	<keyword>lymphoma</keyword>
</DOC>